Paper Details

  1. Home
  2. Paper Details

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.

Author: AdamsAnne, EstcourtLise J, JakobTina, KuhrKathrin, LangerPeter, MonsefIna, OcheniSunday, PiechottaVanessa, ScheckelBenjamin, ScheidChristof, SkoetzNicole, TheurichSebastian

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Multiple myeloma is a type of blood cancer. The main treatment for people who aren't eligible for a stem cell transplant involves a combination of medications like bortezomib, lenalidomide, or thalidomide. However, access to these medications is limited in many countries.
Paper Details　
Original Abstract of the Article :
Multiple myeloma is a bone marrow-based hematological malignancy accounting for approximately two per cent of cancers. First-line treatment for transplant-ineligible individuals consists of multiple drug combinations of bortezomib (V), lenalidomide (R), or thalidomide (T). However, access to these m...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876545/

データ提供：米国国立医学図書館（NLM）

Treating Multiple Myeloma: A Multi-Pronged Attack

Multiple myeloma is a type of cancer that affects the bone marrow. This study investigates the effectiveness of various drug combinations for treating transplant-ineligible individuals with multiple myeloma, comparing the efficacy of regimens involving bortezomib, lenalidomide, and thalidomide. It's like a team of skilled desert warriors, using different weapons and strategies to combat a formidable enemy.

Fighting Multiple Myeloma: A Desert Alliance

This research highlights the importance of finding effective treatment options for multiple myeloma, particularly for patients who are not eligible for bone marrow transplantation. It's like establishing a strategic alliance in the desert, pooling resources and expertise to fight a common enemy.

Fighting Multiple Myeloma: A Desert Alliance

This study underscores the need for continued research and development of new treatments for multiple myeloma. It's like exploring new frontiers in the desert, seeking out innovative solutions to overcome this challenging disease.

Dr.Camel's Conclusion

This study is a testament to the ongoing efforts to combat multiple myeloma. Like a persistent camel caravan, researchers are tirelessly searching for new ways to defeat this disease and improve the lives of those affected.

Date :
  1. Date Completed 2020-04-23
  2. Date Revised 2023-04-12
Further Info :

Pubmed ID

31765002

DOI: Digital Object Identifier

PMC6876545

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.